Author

Agreen Hadadi

Observed name: A. Hadadi

Institutions: Emory University, Winship Cancer Institute

Observed institutions: Navicent Health, Georgia Institute of Technology, Mercer University, Emory University, Mercer University Health Sciences Center, Winship Cancer Institute

ORCID: 0000-0001-7124-4924

Observed ORCID: 0000-0001-7124-4924

OpenAlex ID: A5016199873

Membrane Estrogen Signaling Enhances Tumorigenesis and Metastatic Potential of Breast Cancer Cells via Estrogen Receptor-α36 (ERα36)

2012 · Reyhaan A. Chaudhri, Rene Olivares-Navarrete, et al. · Journal of Biological Chemistry · 107

Estrogen receptor-alpha 36 mediates the anti-apoptotic effect of estradiol in triple negative breast cancer cells via a membrane-associated mechanism

2014 · Reyhaan A. Chaudhri, Agreen Hadadi, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 48

17Beta-Estradiol Promotes Aggressive Laryngeal Cancer Through Membrane-Associated Estrogen Receptor-Alpha 36

2013 · Nofrat Schwartz, Reyhaan A. Chaudhri, et al. · Hormones and Cancer · 33

Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer

2022 · Agreen Hadadi, Katherine ER Smith, et al. · Urologic Oncology Seminars and Original Investigations · 24

The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression

2023 · Agreen Hadadi, Harris B. Krause, et al. · Cancers · 15

Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.

2022 · Grant Rauterkus, Agreen Hadadi, et al. · Journal of Clinical Oncology · 3

Abstract PS3-10-18: Early Discontinuation of Adjuvant Endocrine Therapy in Patients with Triple Positive Early Stage Breast Cancer after Pathologic Complete Response (pCR) to Neoadjuvant Therapy: A Retrospective Review

2026 · A. Hadadi, W. Yang, et al. · Clinical Cancer Research

Abstract P5-05-10: Real-world treatment patterns and clinical outcomes of first-line therapy and first-line maintenance therapy in patients with human epidermal growth factor 2-positive metastatic breast cancer

2025 · Agreen Hadadi, Edward Neuberger, et al. · Clinical Cancer Research

Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HR-negative HER2-low metastatic breast cancer (mBC): A real-world experience.

2025 · Lan Lei, Agreen Hadadi, et al. · Journal of Clinical Oncology

The genomic landscape of urothelial carcinoma with high and low ERBB2/HER2 expression.

2023 · Agreen Hadadi, Harris Krause, et al. · Journal of Clinical Oncology

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report

2022 · Tony Zibo Zhuang, Lara Harik, et al. · Frontiers in Oncology

The Treatment of Triple Negative Breast Cancer: Does Insurance Status Matter?

2018 · Agreen Hadadi, Paul Dale, et al. · The American Surgeon

Abstract 504: ERα36 as a potential target in breast cancer that promotes an aggressive tumor phenotype in vitro and predicts outcome in vivo.

2013 · Reyhaan A. Chaudhri, Agreen Hadadi, et al. · Cancer Research

1054 POSTER 17beta-estradiol Signaling via Estrogen Receptor Alpha-36 Enhances Survival and Invasion of ERalpha-negative Breast Cancer Cells

2011 · R.A. Chaudhri, N. Cuenca, et al. · European Journal of Cancer

[The use of 17 alpha-methyl testosterone for production increase techniques of male Rainbow fishes (Melanotaenia boesemani)]

1997 · Nurhidayat Nurhidayat, Agreen Hadadi

Works count: 15

Citation count: 230

H-index: 5

I10-index: 5